Support from readers like you keeps The Journal open.
You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.
If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.
At the HSE’s usual Thursday media briefing, CEO Paul Reid came armed with ‘bump-in-the-road’ metaphors as he rushed to reassure people that the health service can manage what is the 25th change now to the vaccination programme.
On Monday the National Immunisation Advisory Committee (NIAC) recommended that the AstraZeneca vaccine only be used in those over the age of 60, following concerns about very rare side effects that cause unusual blood clotting events in 4-10 people for every one million doses administered.
On Tuesday, Johnson and Johnson announced its decision to postpone the rollout of its vaccine in Europe. This news came after two US agencies – the Food and Drugs Administration (FDA) and the Centres for Disease Control and Prevention (CDC) – recommended the vaccine be paused “out of an abundance of caution” after six cases of a rare type of blood clot were reported.
Wednesday brought a much-needed positive development as Pfizer agreed a deal with the European Commission to bring forward the delivery of 50 million doses of its vaccine to the second quarter of the year. This will see Ireland receive an additional 545,000 doses over April, May and June.
“There have been many twists along the road, there have been many bumps – some of them rougher than others – there have been many setbacks, there have been many body blows to us along the way,” Reid said on Thursday.
The health service chief has asked the public not to lose sight of the “big picture” aim of the vaccination programme – to reduce illness, hospitalisations and mortality and to protect the country’s most vulnerable people. He urged them not to focus entirely on numbers and targets and forecasts.
But more than two weeks into the all-important second quarter of the year, as the rollout moves onto the 65-69 age cohort, the public focus is still very much on what these significant changes to the vaccination programme will mean for them.
AstraZeneca
The change in advice for the AstraZeneca vaccine means those who are in the high risk and very high risk categories will now receive either the Pfizer or Moderna vaccine – unless they have already received a first dose of AstraZeneca.
Those aged 60 and older should receive their second dose of AZ 12 weeks later as scheduled.
Those aged under 60 years with a very high risk or high-risk medical condition should receive their second dose 12 weeks later as scheduled.
Those aged under 60 years who do not have a very high risk or high-risk medical condition (mostly healthcare workers) should have the scheduled interval between doses extended to 16 weeks to allow further assessment of the benefits and risks as more evidence becomes available.
The AstraZeneca vaccine will now be used solely in those aged over 60 and will be the only vaccine offered to those aged 60-69.
Anyone aged 65-69 who wishes to receive a vaccine can register using the HSE’s online portal or by calling 1850 24 1850. People who are deaf or hard of hearing can text HSE Live on 086 1800 661.
50,000 people have registered for a #COVID19 vaccine since the portal went live yesterday.
Hugely encouraging to see so many people now so close to their vaccine first dose. @HSELive are asking for people aged 68 to register today on: https://t.co/LXV87JtP0a
The HSE and GPs have urged people not to call GP surgeries about receiving a vaccine if they are in this cohort – all queries should go through the HSE and all registration should be through the online portal or the phone line.
Health officials have acknowledged that some people in this cohort may have concerns about receiving the AstraZeneca vaccine following reports of rare but serious blood clotting events. However, this vaccine has been deemed suitable even for those who have a history of blood clots.
These rare blood clotting events occur in 4-10 cases in every million AZ vaccine doses administered, in which one person may die. As of 4 April, 221 cases of these rare events were reported to the European centralised database. Around 34 million people had been vaccinated in the European Economic Area (EEA) and UK by this date.
Evidence shows that these very rare side effects have been mostly seen in people under 60.
The HSE has said those who have a history of blood clots in the family, as well as those who have recently had a clot or who are on blood thinning treatments should still have the AstraZeneca vaccine when offered it. This advice also applies to those who have a condition or who are on treatment that makes them more likely to get a blood clot – they should still get the vaccine.
HSE Chief Clinical Officer Dr Colm Henry this week said balance of benefit is “heavily in favour” of them getting the vaccine as it prevents the most serious consequences of Covid.
Advertisement
“The clots that have been described here with the EMA are unusual venous clots, they’re different from the common clots people have,” he explained.
Dr Henry said the advice is for “anybody in this age group, particularly people with underlying conditions” is they have “everything to gain by getting vaccinated”.
He said only those who have had a very severe reaction to the first dose of the vaccine or a known allergy to a constituent part of the vaccine would be advised against taking it.
In all other circumstances, with all other medical histories, conditions and medications, people aged 60 and over are advised to take the AstraZeneca vaccine.
Officials have said if there is good take-up among the 60-69s, it is unlikely that Ireland will be left with a surplus of the vaccine.
Johnson & Johnson
Paul Reid confirmed this week that the first delivery of 14,000 vaccines from Johnson & Johnson did arrive in Ireland as scheduled, but are now in storage – or “in quarantine”, as Reid put it.
Officials and government have said they expect – or rather hope – the one-dose vaccine will come back on stream over the course of the second quarter of the year.
However current modelling is based on the assumption that this particular vaccine may not be available for use over the quarter.
“It’s a 605,000 delivery for us in the quarter, it is early in the quarter and I don’t know how long it’ll take for the EMA [European Medicines Agency] to come to that consideration,” Reid said.
Pfizer
Thanks to a new deal between Pfizer/BioNTech and the European Commission, Ireland will receive an additional 545,000 doses of the Pfizer vaccine over April, May and June.
Health officials have said this will help to keep the vaccination programme on track, despite changes relating to the AstraZeneca vaccine and the Johnson & Johnson pause.
Consideration is being given to an extension to the gap between first and second doses of mRNA vaccines. Currently there is a four-week gap between the first and second dose of the Pfizer vaccine in Ireland, but internationally the gap has been extended – up to 12 weeks in some cases.
The new schedule
The HSE has warned that any projections it makes now are subject to change, but officials have said the change in advice on the AstraZeneca vaccine and the pause on the Johnson and Johnson jab should not cause significant delays.
The vast majority of those aged over 70 will have received their first dose by the end of next week. The vaccination programme is also focusing now on 250,000 people aged 16 to 59 who are at very high risk. These vaccinations will be done in hospitals, GP surgeries and community vaccination centres.
Around 70,000 have already received a vaccine;
GPs will commence their very high risk patients in late April (around 120,000 people);
16/17-year-olds in this group will be completed in late April using Pfizer (3,000 people);
Vaccination centres and hospitals will recommence appointments next week (after the pause due to the change in advice on the AZ vaccine), with a target of completion in mid-May (50,000 people).
The rollout to the 65-69 cohort will be happening in parallel, but these vaccines will all be administered at a vaccination centre.
The HSE has estimated there are 420,000 people aged 60-69 who are yet to receive a vaccine.
Vaccination for the 65-69 cohort will begin next week and the HSE has said it will take three weeks to give first doses to this group;
Those aged 60-64 will be invited to register for a vaccine in late April.
The HSE has also laid out its plans for Cohort 7, people aged 16 to 64 who are at high risk.
A schedule for GPs is to be finalised with a target of commencing with this group towards the end of April (295,000 people);
Vaccination centres and community vaccination teams will administer vaccines to those with mental health or intellectual disabilities (50,000 people);
The majority are to have received a first dose in early June.
It is still expected, despite all of this week’s changes, that four out of five people will receive their first dose by the end of June.
Readers like you are keeping these stories free for everyone...
A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article.
Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation.
To embed this post, copy the code below on your site
Close
18 Comments
This is YOUR comments community. Stay civil, stay constructive, stay on topic.
Please familiarise yourself with our comments policy
here
before taking part.
'A stain on society': Homelessness hits another record of 15,286 people in emergency accommodation
Updated
21 mins ago
3.9k
Fighter Planes
Simon Harris is 'convinced' that Ireland needs its own squadron of fighter jets
Niall O'Connor
Reports from The Curragh Camp
5 mins ago
17
New Mexico
Police 'keeping everything on the table' in deaths of Gene Hackman and wife Betsy Arakawa
Updated
17 hrs ago
103k
78
Your Cookies. Your Choice.
Cookies help provide our news service while also enabling the advertising needed to fund this work.
We categorise cookies as Necessary, Performance (used to analyse the site performance) and Targeting (used to target advertising which helps us keep this service free).
We and our 153 partners store and access personal data, like browsing data or unique identifiers, on your device. Selecting Accept All enables tracking technologies to support the purposes shown under we and our partners process data to provide. If trackers are disabled, some content and ads you see may not be as relevant to you. You can resurface this menu to change your choices or withdraw consent at any time by clicking the Cookie Preferences link on the bottom of the webpage .Your choices will have effect within our Website. For more details, refer to our Privacy Policy.
We and our vendors process data for the following purposes:
Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a device. Personalised advertising and content, advertising and content measurement, audience research and services development.
Cookies Preference Centre
We process your data to deliver content or advertisements and measure the delivery of such content or advertisements to extract insights about our website. We share this information with our partners on the basis of consent. You may exercise your right to consent, based on a specific purpose below or at a partner level in the link under each purpose. Some vendors may process your data based on their legitimate interests, which does not require your consent. You cannot object to tracking technologies placed to ensure security, prevent fraud, fix errors, or deliver and present advertising and content, and precise geolocation data and active scanning of device characteristics for identification may be used to support this purpose. This exception does not apply to targeted advertising. These choices will be signaled to our vendors participating in the Transparency and Consent Framework.
Manage Consent Preferences
Necessary Cookies
Always Active
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work.
Targeting Cookies
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.
Functional Cookies
These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then these services may not function properly.
Performance Cookies
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not be able to monitor our performance.
Store and/or access information on a device 105 partners can use this purpose
Cookies, device or similar online identifiers (e.g. login-based identifiers, randomly assigned identifiers, network based identifiers) together with other information (e.g. browser type and information, language, screen size, supported technologies etc.) can be stored or read on your device to recognise it each time it connects to an app or to a website, for one or several of the purposes presented here.
Personalised advertising and content, advertising and content measurement, audience research and services development 137 partners can use this purpose
Use limited data to select advertising 106 partners can use this purpose
Advertising presented to you on this service can be based on limited data, such as the website or app you are using, your non-precise location, your device type or which content you are (or have been) interacting with (for example, to limit the number of times an ad is presented to you).
Create profiles for personalised advertising 79 partners can use this purpose
Information about your activity on this service (such as forms you submit, content you look at) can be stored and combined with other information about you (for example, information from your previous activity on this service and other websites or apps) or similar users. This is then used to build or improve a profile about you (that might include possible interests and personal aspects). Your profile can be used (also later) to present advertising that appears more relevant based on your possible interests by this and other entities.
Use profiles to select personalised advertising 78 partners can use this purpose
Advertising presented to you on this service can be based on your advertising profiles, which can reflect your activity on this service or other websites or apps (like the forms you submit, content you look at), possible interests and personal aspects.
Create profiles to personalise content 38 partners can use this purpose
Information about your activity on this service (for instance, forms you submit, non-advertising content you look at) can be stored and combined with other information about you (such as your previous activity on this service or other websites or apps) or similar users. This is then used to build or improve a profile about you (which might for example include possible interests and personal aspects). Your profile can be used (also later) to present content that appears more relevant based on your possible interests, such as by adapting the order in which content is shown to you, so that it is even easier for you to find content that matches your interests.
Use profiles to select personalised content 34 partners can use this purpose
Content presented to you on this service can be based on your content personalisation profiles, which can reflect your activity on this or other services (for instance, the forms you submit, content you look at), possible interests and personal aspects. This can for example be used to adapt the order in which content is shown to you, so that it is even easier for you to find (non-advertising) content that matches your interests.
Measure advertising performance 127 partners can use this purpose
Information regarding which advertising is presented to you and how you interact with it can be used to determine how well an advert has worked for you or other users and whether the goals of the advertising were reached. For instance, whether you saw an ad, whether you clicked on it, whether it led you to buy a product or visit a website, etc. This is very helpful to understand the relevance of advertising campaigns.
Measure content performance 60 partners can use this purpose
Information regarding which content is presented to you and how you interact with it can be used to determine whether the (non-advertising) content e.g. reached its intended audience and matched your interests. For instance, whether you read an article, watch a video, listen to a podcast or look at a product description, how long you spent on this service and the web pages you visit etc. This is very helpful to understand the relevance of (non-advertising) content that is shown to you.
Understand audiences through statistics or combinations of data from different sources 75 partners can use this purpose
Reports can be generated based on the combination of data sets (like user profiles, statistics, market research, analytics data) regarding your interactions and those of other users with advertising or (non-advertising) content to identify common characteristics (for instance, to determine which target audiences are more receptive to an ad campaign or to certain contents).
Develop and improve services 82 partners can use this purpose
Information about your activity on this service, such as your interaction with ads or content, can be very helpful to improve products and services and to build new products and services based on user interactions, the type of audience, etc. This specific purpose does not include the development or improvement of user profiles and identifiers.
Use limited data to select content 39 partners can use this purpose
Content presented to you on this service can be based on limited data, such as the website or app you are using, your non-precise location, your device type, or which content you are (or have been) interacting with (for example, to limit the number of times a video or an article is presented to you).
Use precise geolocation data 43 partners can use this special feature
With your acceptance, your precise location (within a radius of less than 500 metres) may be used in support of the purposes explained in this notice.
Actively scan device characteristics for identification 25 partners can use this special feature
With your acceptance, certain characteristics specific to your device might be requested and used to distinguish it from other devices (such as the installed fonts or plugins, the resolution of your screen) in support of the purposes explained in this notice.
Ensure security, prevent and detect fraud, and fix errors 87 partners can use this special purpose
Always Active
Your data can be used to monitor for and prevent unusual and possibly fraudulent activity (for example, regarding advertising, ad clicks by bots), and ensure systems and processes work properly and securely. It can also be used to correct any problems you, the publisher or the advertiser may encounter in the delivery of content and ads and in your interaction with them.
Deliver and present advertising and content 97 partners can use this special purpose
Always Active
Certain information (like an IP address or device capabilities) is used to ensure the technical compatibility of the content or advertising, and to facilitate the transmission of the content or ad to your device.
Match and combine data from other data sources 69 partners can use this feature
Always Active
Information about your activity on this service may be matched and combined with other information relating to you and originating from various sources (for instance your activity on a separate online service, your use of a loyalty card in-store, or your answers to a survey), in support of the purposes explained in this notice.
Link different devices 51 partners can use this feature
Always Active
In support of the purposes explained in this notice, your device might be considered as likely linked to other devices that belong to you or your household (for instance because you are logged in to the same service on both your phone and your computer, or because you may use the same Internet connection on both devices).
Identify devices based on information transmitted automatically 85 partners can use this feature
Always Active
Your device might be distinguished from other devices based on information it automatically sends when accessing the Internet (for instance, the IP address of your Internet connection or the type of browser you are using) in support of the purposes exposed in this notice.
Save and communicate privacy choices 65 partners can use this special purpose
Always Active
The choices you make regarding the purposes and entities listed in this notice are saved and made available to those entities in the form of digital signals (such as a string of characters). This is necessary in order to enable both this service and those entities to respect such choices.
have your say